ETC 1001

Drug Profile

ETC 1001

Alternative Names: ESP-31015; ETC-1001

Latest Information Update: 10 Dec 2007

Price : $50

At a glance

  • Originator Esperion Therapeutics
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 16 Feb 2004 Esperion Therapeutics has been acquired by and merged into Pfizer
  • 22 Oct 2003 Esperion has completed enrolment in the ETC 1001-001 trial
  • 16 Jul 2003 Phase-I clinical trials in Atherosclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top